Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

被引：0
|
作者：
Austin Lammers
Ruibin Wang
Jeremy Cetnar
Vinay Prasad
机构：
[1] Oregon Health & Science University,Division of Hematology Oncology, Knight Cancer Institute
[2] Johns Hopkins Bloomberg School of Public Health,Department of Epidemiology
[3] Oregon Health & Science University,Department of Public Health and Preventive Medicine
[4] Oregon Health & Science University,Center for Health Care Ethics
来源：
Blood Cancer Journal | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology A Dangerous Precedent?
    Gyawali, Bishal
    Kesselheim, Aaron S.
    JAMA ONCOLOGY, 2019, 5 (05) : 607 - 608
  • [32] A COMPARISON OF ANTIEPILEPTIC DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION AND HEALTH CANADA
    Alsharaimy, F.
    Chong, D.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    Eguale, T.
    VALUE IN HEALTH, 2017, 20 (05) : A199 - A199
  • [33] Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
    Hutchinson, Nora
    Carlisle, Benjamin
    Doussau, Adelaide
    Bosan, Rafia
    Gumnit, Eli
    MacPherson, Amanda
    Fergusson, Dean A.
    Kimmelman, Jonathan
    JAMA NETWORK OPEN, 2021, 4 (05) : E2110456
  • [34] NOVEL DRUG APPROVALS BY THE US FOOD AND DRUG ADMINISTRATION IN RARE DISEASES: FINDINGS FROM 2020-2023
    Dubey, A.
    Gupta, P.
    Ranjan, N.
    Ray, P.
    Kumar, J.
    Shaikh, J.
    VALUE IN HEALTH, 2024, 27 (06) : S216 - S216
  • [35] US Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer
    Ribeiro, Tatiane Bomfim
    Ribeiro, Adalton
    Rodrigues, Luiza de Oliveira
    Harada, Guilherme
    Nobre, Moacyr Roberto Cuce
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (01) : 20 - 28
  • [36] Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013
    Cruz, Marisa L.
    Xu, Jing
    Kashoki, Mwango
    Lurie, Peter
    JAMA INTERNAL MEDICINE, 2017, 177 (08) : 1207 - +
  • [37] Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
    Dhodapkar, Meera
    Zhang, Audrey D.
    Puthumana, Jeremy
    Downing, Nicholas S.
    Shah, Nilay D.
    Ross, Joseph S.
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [38] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Tibau, Ariadna
    Molto, Consolacion
    Ocana, Alberto
    Templeton, Arnoud J.
    Del Carpio, Luis P.
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 486 - 492
  • [39] Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies
    Bonsu, Janice M.
    Kola-Kehinde, Onaopepo
    Kim, Lisa
    Ruz, Patrick
    Campbell, Courtney M.
    Brammer, Jonathan E.
    Addison, Daniel
    JAMA ONCOLOGY, 2021, 7 (11) : 1722 - 1723
  • [40] Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
    Lythgoe, Mark
    Krell, Jonathan
    Warner, Jeremy Lyle
    Desai, Aakash
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345